Background: Oxygen saturation (SpO 2 ) is an important indicator of newborn transition to extra-uterine life, and commonly monitored in the delivery room. A defined reference range for SpO 2 exists, with data derived from a cohort of infants that received early cord clamping (ECC) (Dawson 2009). However, this parameter has not been defined in infants following delayed cord clamping (DCC). We aimed to define a reference range for SpO 2 in infants receiving DCC ≥90 seconds and compare this to the established reference range where infants routinely received ECC.
Background: Oxygen saturation (SpO 2 ) is an important indicator of newborn transition to extra-uterine life, and commonly monitored in the delivery room. A defined reference range for SpO 2 exists, with data derived from a cohort of infants that received early cord clamping (ECC) (Dawson 2009 ). However, this parameter has not been defined in infants following delayed cord clamping (DCC). We aimed to define a reference range for SpO 2 in infants receiving DCC ≥90 seconds and compare this to the established reference range where infants routinely received ECC.
Methods: A prospective observational study measuring SpO 2 in term infants following vaginal delivery. Immediately after birth, a pulse oximeter was applied to the infant's right hand or wrist, and SpO 2 data were collected every 2 seconds for 10 minutes. Infants receiving ECC or resuscitation were excluded.
Results: 257 infants were included, 103 studied in the DCC cohort compared to 154 reported previously in the Dawson ECC cohort. The mean gestational age and birth weight were similar in both groups. The median (IQR) time for cord clamping in the DCC group was 178 (131, 271) seconds. The mean (SD) SpO 2 (%) in the DCC vs ECC groups at 60, 90 and 120 seconds were 75.6 (9.4) vs 68.0 (13.1) (p=0.01), 71.6 (10.9) vs 70.9 (13.7) (p=0.89) and 70.6 (13.4) vs 73.1 (12.0) (p=0.34), respectively.
Conclusions: 60 seconds after birth, infants receiving DCC had a higher SpO 2 value than those receiving ECC. However, at other recorded time points there were no significant differences in SpO 2 . Background: Bronchopulmonary dysplasia (BPD) is a common condition in extreme premature infants. Current management of BPD is largely supportive and no cure exists. Over the last decade, our group has shown that human amnion epithelial cells (hAECs), derived from healthy amniotic membranes can prevent and reverse lung injury in small and large animal models of adult and neonatal lung disease, including BPD.
AMNION EPITHELIAL STEM CELLS FOR ESTABLISHED
Aim: To assess the safety of intravenously administered allogeneic hAECs in preterm infants with established BPD.
Methods: Preterm infants born before 28 weeks of gestation were eligible if they were dependent on pressure support and oxygen at 36 weeks postconceptional age. Primary safety outcome parameters included short term effects -local reaction, anaphylaxis, infection, systemic rejection, and long term effects, including tumorigenesis. CGMP-compliant hAECs were isolated from healthy term placenta donors and delivered to infants using a slow intravenous infusion at a dose of 1 million/ kg suspended in saline. Secondary outcomes included changes in respiratory function.
Results: Six preterm infants (median birth weight 795 (450-990) grams, gestation 26 (24-28) weeks) with established severe BPD were administered hAECs at 89 (59-187) days of life. There were no immediate or short term adverse effects following hAEC transfusion. Respiratory support parameters in the first few days after cell infusion either improved or showed no significant change from pre-treatment levels.
Conclusions: hAECs seem to be well tolerated when given to preterm infants with established severe BPD. This first-in-human study will inform future clinical trials of this novel therapy for BPD. Background: Target glycaemic recommendations for women with gestational diabetes mellitus (GDM) vary widely between international organisations. Although some studies have reported on experiences of women with GDM little is known about how women achieve their recommended glycaemic treatment targets. The aim of this study was to identify enablers and barriers for women with GDM to achieve their optimal glycaemic targets.
ENABLERS AND BARRIERS FOR WOMEN WITH GESTATIONAL DIABETES MELLITUS TO ACHIEVE OPTIMAL GLYCAEMIC CONTROL: A QUALITATIVE STUDY USING THE THEORETICAL DOMAINS FRAMEWORK
Methods: Women with GDM who had at least two week's experience with self-testing capillary blood glucose (CBG) were invited to participate from two large hospitals in New Zealand. A semi-structured interview was developed. Thematic analysis was performed using the Theoretical Domains Framework. The study is nested within the TARGET Trial (ACTRN 12615000282583).
Results: Sixty women participated. Behavioural factors for women with GDM in achieving optimal glycaemic control were identified and provided insights as to how most women accept a diagnosis of GDM, adapt to regular self-monitoring, adhere to recommended glycaemic targets, undertake necessary lifestyle changes. Extended family support was reported as valuable for increasing exercise, eating health meals and regular selfmonitoring of capillary blood glucose concentrations. Further research considerations include the effectiveness of phone apps, the value of engaging a physical activity therapist and possibly a name change for GDM to reduce maternal anxiety.
Conclusions: Women with GDM reported multiple enablers and barriers to achieving optimal glycaemic control. These findings may assist health professionals and diabetes in pregnancy services to improve their care for women with GDM and support them to achieve optimal glycaemic control. 
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